Hypoxia-responsive nanoparticles for tumor-targeted drug delivery

Li, Yuce; Jeon, Jueun; Park, Jae Hyung

doi:10.1016/j.canlet.2020.05.032

Cited by 59 publications

(37 citation statements)

References 87 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, CS‐NBCF micelles exhibited positive potential (8–10 mV), which might be due to the presence of more amino groups than carboxyl groups on the micelle surface. Since micelles with a smaller average particle size might escape from recognition by reticuloendothelial system and prolong their blood circulation time, 33,34 CS‐NBCF‐2 micelles were selected for further research.…”

Section: Resultsmentioning

confidence: 99%

Hypoxia‐sensitive micelles based on amphiphilic chitosan derivatives for drug‐controlled release

Chen

Wen

Guo

2021

Polymers for Advanced Techs

View full text Add to dashboard Cite

Natural chitosan (CS) is composed of a larger hydrophilic skeleton with great biocompatibility. A hypoxia sensitive amphiphilic conjugate (CS‐NBCF) was synthesized by conjugating CS with nitrobenzyl chloroformate (NBCF). Subsequently, nano micelles with high stability (CMC = 0.0030 mg/ml) were formed by self‐assembly of the polymers in deionized water. The hypoxia‐responsive function was demonstrated by examining the size variations of polymeric micelles under the hypoxia conditions. Doxorubicin (DOX) was encapsulated into the micellar core, the drug loading and encapsulation efficiency of DOX were 15.0% and 52.6%, respectively. The in vitro release experiments showed that DOX could be released rapidly in hypoxic environment, and the release amount was up to 68% in 24 h. It was found from the cytotoxicity experiment that that the toxicity of the blank micelles was low, while DOX‐loaded micelles exhibited a good anti‐cancer effect under hypoxic conditions, and the cell inhibition rate of MCF‐7 was high up to 63%. As a result, the demonstrated properties endowed as‐developed polymeric micelles with promising application as drug delivery system in tumor treatment.

show abstract

Section: Resultsmentioning

confidence: 99%

Hypoxia‐sensitive micelles based on amphiphilic chitosan derivatives for drug‐controlled release

Chen

Wen

Guo

2021

Polymers for Advanced Techs

View full text Add to dashboard Cite

show abstract

“…Quantitative proteomics is a promising tool for revealing the molecular mechanisms of drug action. 58 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 Proteomics drug maps have greatly promoted the discovery of drug targets. After the quantitative analysis for 10,000 proteins and 55,000 phosphorylation sites (p-sites) from 125 cancer cell lines, the proteome activity landscapes were obtained.…”

Section: Discovering Drug Targets With Quantitative Proteomicsmentioning

confidence: 99%

Quantitative proteomics characterization of cancer biomarkers and treatment

Yang

Shi

Zhang

et al. 2021

Molecular Therapy - Oncolytics

View full text Add to dashboard Cite

Cancer accounted for 16% of all death worldwide in 2018. Significant progress has been made in understanding tumor occurrence, progression, diagnosis, treatment, and prognosis at the molecular level. However, genomics changes cannot truly reflect the state of protein activity in the body due to the poor correlation between genes and proteins. Quantitative proteomics, capable of quantifying the relatively different protein abundance in cancer patients, has been increasingly adopted in cancer research. Quantitative proteomics has great application potentials, including cancer diagnosis, personalized therapeutic drug selection, real-time therapeutic effects and toxicity evaluation, prognosis and drug resistance evaluation, and new therapeutic target discovery. In this review, the development, testing samples, and detection methods of quantitative proteomics are introduced. The biomarkers identified by quantitative proteomics for clinical diagnosis, prognosis, and drug resistance are reviewed. The challenges and prospects of quantitative proteomics for personalized medicine are also discussed.

show abstract

“…14 To realize the on-demand release, a series of tumor related stimulus have been employed to design stimuli-triggered drug delivery systems. A series of endotrigger stimulies, such as pH, 15 hypoxia, 16 enzyme, 17 temperature, 18 redox, 19,20 glucose 21,22 and other exotrigger stimuli such as light, 23 electric, 24 magnetic, 25 and ultrasound 26 responsive drug delivery systems have been well documented. 27 For the design of these stimuli-triggered drug delivery systems, DNA molecules have been shown to be excellent substrates for the design and construction of intelligent vehicles for imaging and cargo delivery.…”

Section: Introductionmentioning

confidence: 99%